Currently viewing the tag: "Q1"
Today BioPorto released its Q1 figures. Nothing much was expected, and nothing much was indeed the outcome. I will, as always, start with focusing on the area(s) that are disappointing. But don’t despair yet – hopefully I’ll end on a lighter note
If we look at the turnover – it was perhaps in accordance with […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard

